Patients with cancer are nowadays better treated than before. However, cancer survivors often suffer from neurological complications after exposure to anticancer therapy. Chemotherapy-induced peripheral neurotoxicity (CIPN) with sensory loss and neuropathic pain in the extremities is most encountered. In this workshop the three speakers will cover new advances in the pathophysiology of CIPN and transfer preclinical pathways in the clinic. Dr. Dougherty will explore excitability of primary sensory neurons and the contribution of voltage gated channels to the pathophysiology of allodynia in taxane-, platin- and bortezomib-related CIPN. Different channels govern the development and maintenance of CIPN – some of which could be targeted by existing drugs or useful for development. Dr. Rittner will focus on non-neuronal cells controlling bortezomib-induced polyneuropathy. Nerve barriers and their preservation with growth factors are important axonal protectors. Preventing their damage e.g., by enforcing neuronal barriers could help to shield the nerve. Dr. Alberti will address the clinical phenotype of CIPN and two types of oxaliplatin-induced neurotoxicity, early (i.e., hyperexcitability) and delayed (chronic neuropathy). She will especially enlighten the challenges of translating diseases into preclinical models applying translational outcome measures as the basis for phase I clinical trials. Finally, all speakers will discuss the next steps to implement their findings into the clinic.